

# The biodegradation of hydroxyapatite bone graft substitutes *in vivo*

E. Rumpel<sup>1</sup>, E. Wolf<sup>2</sup>, E. Kauschke<sup>1</sup>, V. Bienengräber<sup>3</sup>, T. Bayerlein<sup>4</sup>,  
T. Gedrange<sup>4</sup>, P. Proff<sup>4</sup>

<sup>1</sup>Institute of Anatomy and Cell Biology, Ernst Moritz Arndt University, Greifswald, Germany

<sup>2</sup>Institute of Pathology, Hanse Klinikum Stralsund, Stralsund, Germany

<sup>3</sup>Clinic for Cranio-Maxillofacial and Plastic Surgery, University of Rostock, Germany

<sup>4</sup>Clinic for Orthodontics and Preventive and Paediatric Dentistry, University of Greifswald Dental School, Greifswald, Germany

[Received 21 December 2005; Accepted 8 February 2006]

*Hydroxyapatite (HA) ceramics are widely used for bone reconstruction. They are osteoconductive and serve as structural scaffolds for the deposition of new bone. Generally, scaffold materials should be degradable as they affect the mechanical properties of the reconstructed bone negatively. Degradation by osteoclasts during the bone remodelling process is desirable but often does not take place. In the current study we analysed by light microscopy the degradation of two granular HA implants in critically sized defects in the mandibula of Goettingen mini-pigs five weeks after implantation. Bio-Oss<sup>®</sup> consists of sintered bovine bone and NanoBone<sup>®</sup> is a synthetic HA produced in a sol-gel process in the presence of SiO<sub>2</sub>. We found that both biomaterials were degraded by osteoclasts with ruffled borders and acid phosphatase activity. The osteoclasts created resorption lacunae and resorptive trails and contained mineral particles. Frequently, resorption surfaces were in direct contact with bone formative surfaces on one granule. Granules, especially of NanoBone<sup>®</sup>, were also covered by osteoclasts if located in vascularised connective tissue distant from bone tissue. However, this usually occurred without the creation of resorption lacunae. The former defect margins consisted of newly formed bone often without remnants of bone substitutes. Our results show that the degradation of both biomaterials corresponds to the natural bone degradation processes and suggest the possibility of complete resorption during bone remodelling.*

**Key words: osteoclasts, bone defects, Goettingen miniature pig, mandibula**

## INTRODUCTION

The high incidence of morbidity during autogenous bone grafting has been the rationale for the increase in applications of bone substitute materials. Hydroxyapatite (HA) ceramics, produced synthetically or by processing biological substrates, have been widely and successfully used for bone reconstruc-

tion. They are available as granules, as blocks with pores of different sizes or as injectable material. In any case, owing to its osteoconductive capacity, HA serves as a structural scaffold for the building of new bone tissue. The scaffold itself should be completely degradable, as remnants could affect the mechanical properties of reconstructed bone negatively and,

---

Address for correspondence: Dr. E. Rumpel, Institute of Anatomy and Cell Biology, Ernst Moritz Arndt University Greifswald, Fr. Loeffler Strasse 23c, D-17487 Greifswald, Germany, tel: +49 3834 865319, fax: +49 3834 865302, e-mail: rumpel@uni-greifswald.de

as non-self, may induce inflammation. It is desirable for scaffold degradation to take place during the regular bone remodelling processes [28]. The extent and distribution of the remodelling of bone substitutes are influenced by the quality of the host site and the local mechanical environment [2]. Particles of HA ceramics are often detectable in patients even years after implantation.

The biodegradation of HA scaffolds may take place by dissolution or fragmentation with subsequent phagocytosis by macrophages [8] but also by the activity of osteoclasts [6, 25, 34]. The latter mechanism of biodegradation is favourable [30], because mimicry of the physiological bone processes should create optimal surfaces for colonisation with osteoblasts and vascular tissue. The degree of osteoclast activity on HA scaffolds depends on material qualities such as crystal size [6, 23, 25] and surface roughness [14]. Macrocrystalline HA is not degradable by osteoclasts [24, 32], but microcrystalline HA may also escape resorption, if the biomaterials were sintered during production [26].

We studied the cellular biodegradation of two granular microcrystalline HA implants in critically sized defects in the mandibula of Goettingen miniature pigs. Bio-Oss® is an HA ceramic produced by sintering bovine spongious bone and is extensively used as a bone substitute. NanoBone® is a synthetic HA with nano- and micropores manufactured in a sol-gel process in the presence of SiO<sub>2</sub> [12]. It has been available commercially since 2005. Using light microscopy we made a comparative analysis of the distribution and activities of osteoclastic cells on these biomaterials five weeks after implantation.

## MATERIAL AND METHODS

### Animals

Six adult Goettingen miniature pigs (Ellgaard, Dalmoose, Denmark) of 25–30 kg body weight were used in this study. The animals were kept free in an appropriate facility. Standard mini-pig diet and tap water were available *ad libitum*. The animals were handled in agreement with the European Communities Council Directive of November 24, 1986. The experiments were performed with the permission of the local ethics committee.

### Grafting materials

Bio-Oss® (Geistlich-Pharma, Wolhusen, Switzerland) is a sintered HA ceramic derived from deproteinised bovine spongious bone and was used as

granules of 1–2 mm diameter. NanoBone® (Artoss GmbH, Rostock, Germany) contains 74% unsintered HA and 24% SiO<sub>2</sub> and is manufactured in a sol-gel process. It was used as granules measuring about 0.6 × 2 mm.

### Critically sized defects and insertion of biomaterials

Bone perforating critically sized defects (about 3 × 1.5 × 1.3 cm; > 5 cm<sup>3</sup>) were placed bilaterally in the anterior part of the corpus mandibulae basal to the teeth, leaving the lingual periosteum intact. The defects were filled with the biomaterial mixed with blood (N = 3 animals per tested material) and closed with the vestibular periosteum and skin. For further details and for handling of the animals during surgery see Henkel et al. [16].

The animals were killed by an intracardial injection of pentobarbital five weeks *post operationem*.

### Histological analysis


The defects were fixated in toto in 4% buffered formaldehyde for a minimum of 7 days before cutting transversally into 4 mm thick blocks. Undecalcified blocks were embedded in methacrylate resins (Technovit 7200 VLC, Technovit 9100<sup>NEW</sup>, Kultzer & Co, Wehrhein, Germany) for the sawing-grinding technique [9] and the preparation of thin sections. Samples decalcified with EDTA were embedded in paraffin. Sections were stained with haematoxylin & eosin (HE), toluidine blue, Giemsa, Goldner's trichrome or silver nitrite (von Kossa stain). Evaluation of tartrate-resistant acid phosphatase (TRAP) activity was made with naphthol AS-BI phosphate and pararosaniline.

For the microscopic evaluation we used a photomicroscope (Axioplan, Zeiss, Germany) and the software Analysis® (Soft Imaging Systems, Münster, Germany).

## RESULTS

### General findings

With one exception, there was a complete bridging of the lingual wall of the defects by newly formed bone tissue surrounding granules of the biomaterials (Fig. 1A). The new bone was compact, but locally cancellous. Remodelling was evident as young osteons with large vascular channels embedded in woven bone. The peripheral parts of the former defects consisted of new bone with only minimal biomaterial remnants or none at all (Fig. 1B).



**Figure 1.** Light microscopy of bone defects in the mandibula of mini-pigs five weeks after implantation of bone substitute materials. **A.** Lingual the centre of a defect filled with NanoBone® is bridged with bone surrounding NanoBone® granules (stars). Bone and granules are in the process of remodelling. **B.** Margin of a former defect displaying small remnants of Bio-Oss® (stars). **C., D.** Osteoclasts with visible ruffled borders (arrows) are situated in resorption lacunae of bone (**C**) and Bio-Oss® (**D**). **E., F.** High numbers of osteoclasts attach to surface and to formerly vascular channels (stars in **E**) of Bio-Oss® granules located near bone. They may also form resorptive trails (star in **F**). Thick plastic sections, toluidine blue. Scale bars are given in the lower right corner of the micrographs.

The vestibular wall of the defects was bridged by thin trabeculae of woven bone contacting granules of biomaterial surrounded mainly by connective tissue. In the centre of the defects these walls con-

tained only connective tissue and biomaterial. The region of the former canalis mandibularis consisted partly of osseous trabeculae but mainly of connective tissue and granules.


### Degradation of NanoBone® and Bio-Oss® implants

In all the histological samples analysed multinuclear cells attached to the surface of biomaterial granules were observed. These had the same shape and size as osteoclasts adhering to bone tissue (Fig. 1C, D). Most of these cells demonstrated the features of osteoclasts such as polarisation, ruffled border and TRAP activity (Fig. 1D; 2A, C). Signs of osteoclastic resorption of the biomaterials were evident as resorption lacunae on the granule surface (Fig. 1C, F; 2A, C) and, in the case of Bio-Oss®, in the formerly vascular osteon channels of this bovine biomaterial (Fig. 1E). The dimensions of the lacunae corresponded to those on bone surfaces in our samples. However, the proportion of osteoclasts lying in erosion lacunae was smaller than in bone tissue. There was also evidence of resorptive trail formation in Nano-

Bone® (Fig. 2C) as well as in Bio-Oss® (Fig. 1F). In Bio-Oss® this was identified by osteoclasts situated in channels not surrounded by bone lamellae (Fig. 1F).

The cytoplasm of osteoclasts located on biomaterial often contained differently sized vacuoles and particles stained with toluidine blue, Goldner's trichrome and von Kossa (Fig. 2A, C, D). Such particles were also found near the free surfaces of these cells.

Osteoclasts attached to biomaterial were regularly found in areas with new formation of bone and remodelling respectively, though not on all granules. Frequently bone formation and resorption of the biomaterial proceeded in direct continuity on the granules (Fig. 1F; 2A). Osteoclasts attached to granules also occurred in defect regions without visible bone formation. This was true especially for NanoBone® implants, where granules in the connective tissue were often completely surrounded



**Figure 2.** Light microscopy of bone defects in the mandibula of mini-pigs five weeks after implantation of NanoBone®. **A.** Bone deposition (white arrowheads) and osteoclastic resorption (black arrowheads) proceed in direct continuity on a granule. **B.** Granules surrounded only by connective tissue may be covered with TRAP-active osteoclasts but rarely show resorption lacunae. **C.** Osteoclasts containing particles and demonstrating ruffled borders (arrows) are attached to a granule. **D.** The particles in the cytoplasm of osteoclasts (arrows) are stainable with Goldner's trichrome and von Kossa (inset). **A., C.** Thick plastic sections, toluidine blue. **B.** Paraffin section, TRAP activity. **D.** Thin plastic sections, Goldner's trichrome and von Kossa (inset) respectively. Scale bars are given in the lower right corner of the micrographs.

by multinuclear cells. These cells were TRAP-reactive, but rarely situated in resorption lacunae. Large multinuclear cells without the features of osteoclasts only occasionally contacted granules of either biomaterial.

## DISCUSSION

In the experimental design used for this study we were able to demonstrate that two bone replacement materials based on hydroxyapatite are degraded by osteoclasts. The periphery of the former defects consisted of newly formed bone without biomaterial residues, demonstrating that complete biodegradation of the tested materials is possible. Concerning NanoBone<sup>®</sup>, this confirms the results of other studies carried out with the same animal model [3, 15, 27], which have reported only small amounts of the material eight months after implantation. The fast, extensive degradation of NanoBone<sup>®</sup> is explained by a high degree of nano- and microporosity and a loose arrangement of small HA crystals [12], physical properties that promote degradation [11, 13, 18, 19, 24].

Concerning the biodegradation of Bio-Oss<sup>®</sup>, opinions in the literature vary but the prevalent view is of resorbability [10]. However, Duda and Pajak [10], amongst others, have observed Bio-Oss<sup>®</sup> remnants in patients even years after implantation. Experiments performed in the cranial bones of dogs [22, 31] could not demonstrate signs of biodegradation after several months, while in goats degradation by osteoclast-like cells was found [21]. A recent human study [35] also reports degradation by osteoclasts. The reasons for the conflicting results may lie in factors such as animal model, implantation site and the local mechanical environment, which influence the remodelling of bone substitute materials [2, 20]. An impressive example of the influence of mechanical forces is described for orthodontic movements in the dog, where 12 months after implantation Bio-Oss<sup>®</sup> remained an inactive filler in non-utilised areas of the mandibula but was extensively degraded in zones with mechanical strain [1]. Such zones must be constantly remodelled and we found osteoclasts resorbing biomaterial predominantly in defect areas with extensive bone remodelling. During the remodelling processes osteoclasts form channels in the first, rapidly formed woven bone, which are filled by vascularised connective tissue. To the extent that these channels come into contact with biomaterial, osteoclast progenitor cells may attach to the granules and differentiate to active cells. In our study degradation was characterised by resorption pits and trails

in HA granules, but also by small mineral particles within and near the attached osteoclasts. Thus the removal of biomaterial resorption products by osteoclasts seems to follow the mechanisms demonstrated for bone [29]. That osteoclasts simultaneously resorb and phagocytise calcium phosphate ceramics was demonstrated by transmission electron microscopy *in vitro* [7, 17, 39] and *in vivo* [34]. We found evidence, as did Wenisch et al. [34], that material released into the extracellular space can then be phagocytised by mononuclear macrophages.

Osteoclasts were also attached to granules situated in vascularised connective tissue in areas without bone formation (a defect centre on the vestibular side). We observed this especially after implantation of NanoBone<sup>®</sup>. This reflects the situation in natural bone, where the arrival of osteoclasts is triggered by bare mineralised bone surfaces created by the activity of collagenases [5]. However, on NanoBone<sup>®</sup> embedded in connective tissue osteoclasts were rarely situated in resorption lacunae. This suggests that activating signals [4] are lacking in these regions. For the maintenance of the scaffold function of bone substitutes the inactivity of osteoclasts on biomaterial in areas without bone formation is imperative.

## ACKNOWLEDGEMENTS

The authors would like to thank ARTOSS GmbH for providing the bone graft material NanoBone<sup>®</sup>.

## REFERENCES

1. Araujo MG, Carmagnola D, Berglundh T, Thilander B, Lindhe J (2001) Orthodontic movement in bone defects augmented with Bio-Oss. An experimental study in dogs. *J Clin Periodontol*, 28: 73–80.
2. Bauer TW, Muschler GF (2000) Bone graft materials. An overview of the basic science. *Clin Orthop Relat Res*, 371: 10–27.
3. Bienengraber V, Henkel KO, Rumpel E, Kauschke E, Allegrini S Jr., Gerber T (2005) Entwicklung eines innovativen Knochenaufbaumaterials auf Hydroxylapatit-Xerogel-Basis — Testung im Tierversuch. *Deut Zahnärztl Z*, 60: 39–40.
4. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. *Nature*, 423: 337–342.
5. Chambers TJ, Fuller K (1985) Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. *J Cell Sci*, 76: 155–165.
6. Constantz BR, Ison IC, Fulmer MT, Poser RD, Smith ST, VanWagoner M, Ross J, Goldstein SA, Jupiter JB, Rosenthal DI (1995) Skeletal repair by *in situ* formation of the mineral phase of bone. *Science*, 267: 1796–1799.

7. Contractor T, Babiarz B, Kowalski AJ, Rittling SR, Sorensen ES, Denhardt DT (2005) Osteoclasts resorb protein-free mineral (Osteologic discs) efficiently in the absence of osteopontin. *In Vivo*, 19: 335–341.
8. De Groot K (1985) Clinical usefulness of calcium phosphate ceramics. *Zahnärztl Mitt*, 75: 1938–1940.
9. Donath K, Breuner G (1982) A method for the study of undecalcified bones and teeth attached to soft tissue. The Sägeschliff-technique. *J Oral Pathol*, 11: 438–440.
10. Duda M, Pajak J (2004) The issue of bioresorption of the Bio-Oss xenogeneic bone substitute in bone defects. *Ann Univ Mariae Curie Skłodowska [Med]*, 59: 269–277.
11. Eggli PS, Müller W, Schenk RK (1988) Porous hydroxyapatite and tricalciumphosphate cylinders with two different pore size ranges implanted in the cancellous bone of rabbits. *Clin Orthop Rel Res*, 232: 127–138.
12. Gerber T, Holzhüter G, Knoblich B, Dörfling P, Bienengraber V, Henkel K-O (2000) Development of bioactive sol-gel material template for *in vitro* and *in vivo* synthesis of bone material. *J Sol-Gel Sci Technol*, 19: 441–445.
13. Gibson IR, Hing KA, Revell PA, Santos JD, Best SM, Bonfield W (2002) Enhanced *in vivo* response to silicate-substituted hydroxyapatite. *Key Eng Mater*, 218–220: 105–117.
14. Gomi K, Lowenberg B, Shapiro G, Davies JE (1993) Resorption of sintered synthetic hydroxyapatite by osteoclasts *in vitro*. *Biomaterials*, 14: 91–96.
15. Henkel K-O, Gerber T, Dietrich W, Bienengraber V (2004) Neuartiges Knochenaufbaumaterial auf Kalziumphosphatbasis. *Mund Kiefer GesichtsChir*, 8: 277–281.
16. Henkel K-O, Gerber T, Dörfling P, Gundlach KKH, Bienengraber V (2002) Stimulation der Regeneration von Knochendefekten durch Einsatz einer Biokeramik und autologer Osteoblastentransplantation. *Mund Kiefer GesichtsChir*, 5: 59–65.
17. Heymann D, Guicheux J, Rousselle AV (2001) Ultrastructural evidence *in vitro* of osteoclast-induced degradation of calcium phosphate ceramic by simultaneous resorption and phagocytosis mechanisms. *Histol Histopathol*, 16: 37–44.
18. Klein CPAT, de Groot K, Driessen AA, van der Lubbe HBM (1986) A comparative study of different  $\beta$ -whitlockite ceramics in rabbit cortical bone with regard to their biodegradation behaviour. *Biomaterials*, 7: 144–146.
19. Klein CPAT, van der Lubbe HBM, Driessen AA, de Groot K, van den Hoof A (1983) Biodegradation behaviour of various calciumphosphate materials in subcutaneous tissue. In: Vincencini P (ed.) *Ceramics in surgery*. Elsevier, Amsterdam, pp. 105–115.
20. Lu JX, Gallur A, Flautre B, Anselme K, Descamps M, Thierry B, Hardouin P (1998) Comparative study of tissue reactions to calcium phosphate ceramics among cancellous, cortical, and medullar bone sites in rabbits. *J Biomed Mater Res*, 42: 357–367.
21. Merckx MA, Maltha JC, Freihofer HP, Kuipers-Jagtman AM (1999) Incorporation of three types of bone block implants in the facial skeleton. *Biomaterials*, 20: 639–645.
22. Merckx MA, Maltha JC, van't Hoff M, Kuijpers-Jagtman AM, Freihofer HP (1997) Tooth eruption through autogenous and xenogenous bone transplants: a histological and radiographic evaluation in beagle dogs. *J Cranio-maxillofac Surg*, 25: 212–219.
23. Müller-Mai CM, Voigt C, Gross U (1990) Incorporation and degradation of hydroxyapatite implants of different surface roughness and surface structure in bone. *Scanning Microsc*, 4: 613–624.
24. Müller-Mai C, Voigt C, Hering A, Rahmzadeh R, Gross U (2001) Madreporic hydroxyapatite granulates for filling bone defects. *Unfallchirurg*, 104: 221–229.
25. Müller-Mai CM, Stupp SI, Voigt C, Gross U (1995) Nanoapatite and organoapatite implants in bone: Histology and ultrastructure of the interface. *J Biomed Mater Res*, 29: 9–18.
26. Rueger JM (1998) Bone substitution materials. Current status and prospects. *Orthopäde*, 27: 72–79.
27. Rumpel E, Kauschke E, Allegrini Jr S, Gerber T, Henkel K-O, Bienengraber V (2005) Biologischer Abbau von Knochenersatzmaterialien im Unterkiefer — eine tierexperimentelle Studie. *Deut Zahnärztl Z*, 60: 33–34.
28. Sailer HF, Weber FE (2000) Knochenersatzmaterialien. *Mund Kiefer GesichtsChir*, 4: 384–391.
29. Salo J, Lehenkari P, Mulari M, Metsikkö K, Väänänen JK (1997) Removal of osteoclast bone resorption products by transcytosis. *Science*, 276: 270–273.
30. Schenk RK (1991) Zur Problematik der Knochenersatzstoffe: Histophysiologie des Knochenumbaus und der Substitution von Knochenersatzstoffen. In: Huggler AH, Kuner EH (eds.) *Hefte Unfallheilkd*, 216: 23–35.
31. Schlegel KA, Fichtner G, Schultze-Mosgau S, Wiltfang J (2003) Histological findings in sinus augmentation with autogenous bone chips versus bovine bone substitute. *Int J Oral Maxillofac Implants*, 18: 53–58.
32. Shimizu H, Sakamoto S, Sakamoto M, Lee DD (1989) The effect of substrate composition and condition on resorption by isolated osteoclasts. *Bone Mineral*, 6: 261–275.
33. Tayler JC, Cuff SE, Leger JP, Morra A, Anderson GI (2002) *In vitro* osteoclast resorption of bone substitute biomaterials used for implant site augmentation: a pilot study. *Int J Oral Maxillofac Implants*, 17: 321–330.
34. Wenisch S, Stahl JP, Horas U, Heis C, Kilian O, Trinkaus K, Hild A, Schnettler R (2003) *In vivo* mechanisms of hydroxyapatite ceramic degradation by osteoclasts: fine structural microscopy. *J Biomed Res A*, 67: 713–718.
35. Zaffe D, Leghissa GC, Pradelli J, Botticelli AR (2005) Histological study on sinus lift grafting by Fisiograf and Bio-Oss. *J Mat Sci Mat Med*, 16: 789–793.